ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $20,782 | -100.0% | 165,000 | -52.9% | 0.53% | -82.1% |
| Q2 2020 | $51,765,000 | -14.4% | 350,000 | -34.8% | 2.96% | -17.9% |
| Q1 2020 | $60,439,000 | -34.5% | 536,710 | -19.0% | 3.61% | -23.1% |
| Q4 2019 | $92,237,000 | +47.3% | 663,000 | +2.0% | 4.69% | +42.6% |
| Q3 2019 | $62,608,000 | -16.4% | 650,000 | 0.0% | 3.29% | -5.6% |
| Q2 2019 | $74,848,000 | +47.9% | 650,000 | +51.2% | 3.49% | +38.3% |
| Q1 2019 | $50,611,000 | – | 430,000 | – | 2.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |